Article
Gastroenterology & Hepatology
Siddharth Singh, Jihoon Kim, Jiyu Luo, Paulina Paul, Vivek Rudrapatna, Sunhee Park, Kai Zheng, Gaurav Syal, Christina Ha, Phillip Fleshner, Dermot McGovern, Jenny S. Sauk, Berkeley Limketkai, Parambir S. Dulai, Brigid S. Boland, Samuel Eisenstein, Sonia Ramamoorthy, Gil Melmed, Uma Mahadevan, William J. Sandborn, Lucila Ohno-Machado
Summary: This study compared the safety and effectiveness of three drugs, tumor necrosis factor a (TNF-a) antagonists, vedolizumab, and ustekinumab, in the treatment of patients with Crohn's disease. The results showed that ustekinumab was associated with a lower risk of serious infections compared to TNF-a antagonists and vedolizumab, with no differences in hospitalization or surgery risk. Compared to vedolizumab, ustekinumab-treated patients also had a lower risk of serious infections, but no significant differences in hospitalization or surgery risk.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Immunology
Alison D. Petro, Joseph Dougherty, Bryant R. England, Harlan Sayles, Michael J. Duryee, Carlos D. Hunter, Joel M. Kremer, Dimitrios A. Pappas, William H. Robinson, Jeffrey R. Curtis, Geoffrey M. Thiele, Ted R. Mikuls
Summary: In rheumatoid arthritis patients, the number of positive autoantibodies is dose-dependently associated with treatment response to biologics, with anti-CCP antibody positivity having the strongest impact.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Gastroenterology & Hepatology
Frank I. Scott, Amneet K. Hans, Mark E. Gerich, Blair Fennimore, Ronac Mamtani, Ravy K. Vajravelu, James D. Lewis
Summary: In simulation study, ustekinumab as the first-line biologic therapy for a 35-year-old male patient with moderate to severe CD yielded greater QALYs at the end of 1 year compared with its use later in the CD treatment algorithm.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Review
Gastroenterology & Hepatology
Mohammad Shehab, Fatema Alrashed, Valerie Heron, Sophie Restellini, Talat Bessissow
Summary: This is the first systematic review and network meta-analysis comparing the effectiveness of biologic therapies in inducing response and remission in patients with fistulizing Crohn's disease. The study found that anti-tumor necrosis factor agents are effective in inducing response and remission. Infliximab was superior to adalimumab in inducing response but not in inducing remission.
INFLAMMATORY BOWEL DISEASES
(2023)
Review
Medicine, General & Internal
F. Piehl
Summary: Treatment of multiple sclerosis is evolving with the approval of novel and increasingly effective disease-modulatory therapies. In clinical development, inhibitors of Bruton's tyrosine kinase represent a new emerging drug class in MS. Accumulating evidence suggests the importance of early high effective therapy while maintaining acceptable tolerability.
JOURNAL OF INTERNAL MEDICINE
(2021)
Review
Biochemistry & Molecular Biology
Juan Liu, Bin Di, Li-li Xu
Summary: Inflammatory bowel disease (IBD) is effectively treated with multiple options, and new therapies are actively being explored to provide more choices. Biologic agents and small molecule drugs for ulcerative colitis and Crohn's disease have evolved to have fewer side effects and more accurate targeting. Novel inhibitors targeting cytokines, integrins, cytokine signaling pathways, and cell signaling receptors have become preferred treatments for many IBD patients. Conventional therapies continue to show therapeutic efficacy, particularly when combined with drug therapy.
CYTOKINE & GROWTH FACTOR REVIEWS
(2023)
Article
Medicine, General & Internal
Yukari Okubo, Ann Chuo Tang, Sachie Inoue, Hitoe Torisu-Itakura, Mamitaro Ohtsuki
Summary: The study found that patients and physicians using biologics have higher treatment goals compared to non-biologics users, and biologic users also reported higher treatment satisfaction. Setting appropriate treatment goals that are shared between patients and their physicians may lead to better treatment outcomes.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Medicine, General & Internal
Eduard Brunet, Emili Vela, Luigi Melcarne, Laura-Patricia Llovet, Anna Puy, Montserrat Cleries, Caridad Pontes, Pilar Garcia-Iglesias, Albert Villoria, Gilaad G. Kaplan, Xavier Calvet
Summary: This study observed a remarkable geographical heterogeneity in the utilization of different treatments and outcomes for Crohn's disease patients in Catalonia. There was variability in the use of systemic corticosteroids, non-biological and biological immunosuppressant treatments, as well as hospitalization and surgical intervention rates across different geographical areas.
ANNALS OF MEDICINE
(2022)
Review
Medicine, General & Internal
Francesca Regola, Martina Uzzo, Paola Toniati, Barbara Trezzi, Renato Alberto Sinico, Franco Franceschini
Summary: Takayasu Arteritis is a vascular inflammation that primarily affects the aorta, and cardiac involvement is a major factor in patient outcomes. Glucocorticoids are the main treatment, but have potential adverse effects and relapse rates. Therefore, new therapeutic approaches targeting the IL-6 and TNF-alpha pathways are being researched.
FRONTIERS IN MEDICINE
(2022)
Article
Gastroenterology & Hepatology
Fabio Salvatore Macaluso, Mariabeatrice Principi, Federica Facciotti, Antonella Contaldo, Alessia Todeschini, Simone Saibeni, Cristina Bezzio, Fabiana Castiglione, Olga Maria Nardone, Rocco Spagnuolo, Massimo Claudio Fantini, Gaia Riguccio, Flavio Caprioli, Chiara Vigano, Carla Felice, Gionata Fiorino, Carmen Correale, Giorgia Bodini, Monica Milla, Giulia Scardino, Marta Vernero, Federico Desideri, Mariella Mannino, Giuseppe Rizzo, Ambrogio Orlando
Summary: The study investigated the humoral response to COVID-19 vaccines in patients with inflammatory bowel disease (IBD) treated with immunomodulatory or biological drugs. The majority of IBD patients showed seropositivity after COVID-19 vaccination, but the magnitude of the humoral response was significantly lower compared to healthy controls. These findings suggest that the lower response is mostly unrelated to the use of immune-modifying treatments.
DIGESTIVE AND LIVER DISEASE
(2023)
Review
Biochemistry & Molecular Biology
Niranjan G. Kotla, Yury Rochev
Summary: The pathogenesis of inflammatory bowel disease (IBD) is characterized by gut mucosal inflammation, epithelial damage, and dysbiosis, resulting in a disturbed gut mucosal barrier. Current treatment regimens focus on symptom relief but do not address mucosal epithelial repair, barrier homeostasis, or intestinal dysbiosis. Efforts to identify new therapeutic modalities to enhance gut barrier functions are still in the early developmental stage and have not been entirely successful. In this review, we discuss conventional therapies, the potential role of gut barrier-protecting agents, and biomaterial strategies related to combination therapies that may lead to the development of new therapeutic approaches for IBD.
TRENDS IN MOLECULAR MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Yanni Fan, Ling Zhang, Negar Omidakhsh, Rhonda L. Bohn, Jennifer S. Thompson, Kimberly G. Brodovicz, Parakkal Deepak
Summary: Patients with complicated Crohn's disease (CD) phenotypes have a higher disease burden despite greater use of biologics compared to patients with inflammatory CD. Early recognition and optimized management of CD could prevent progression to complicated phenotypes.
INFLAMMATORY BOWEL DISEASES
(2023)
Review
Biochemistry & Molecular Biology
Giulia Scioscia, Santi Nolasco, Raffaele Campisi, Carla Maria Irene Quarato, Cristiano Caruso, Corrado Pelaia, Andrea Portacci, Claudia Crimi
Summary: Currently, Italy offers three classes of monoclonal antibodies for severe asthma treatment: anti-IgE (Omalizumab), anti-IL-5/anti-IL-5Ra (Mepolizumab and Benralizumab), and anti-IL-4Ra (Dupilumab). Studies have been conducted to determine their efficacy and identify predictors of treatment outcomes. Switching to another monoclonal antibody is recommended if there are no benefits. The choice of treatment should consider the patient's clinical history, biomarkers, and comorbidities.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Gastroenterology & Hepatology
Fabio Salvatore Macaluso, Marco Ventimiglia, Walter Fries, Anna Viola, Aldo Sitibondo, Maria Cappello, Barbara Scrivo, Anita Busacca, Antonino Carlo Privitera, Salvatore Camilleri, Serena Garufi, Roberto Di Mitri, Filippo Mocciaro, Nunzio Belluardo, Emiliano Giangreco, Carmelo Bertolami, Sara Renna, Rosalba Orlando, Giulia Rizzuto, Mario Cottone, Ambrogio Orlando
Summary: In this study comparing VDZ and ADA in CD using propensity score analysis, the drugs showed comparable effectiveness and a similar safety profile.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Dermatology
April Armstrong, Qian Xia, Anand Rojer John, Vardhaman Patel, Lauren Seigel
Summary: This study evaluated the treatment patterns of patients with psoriasis who switched therapies after initiating targeted therapy. The findings showed that patients often reinitiated targeted therapy after using non-targeted therapy. This research provides new insights for considering real-world treatment patterns in future economic models.
DERMATOLOGY AND THERAPY
(2022)
Article
Gastroenterology & Hepatology
Carlos Lago-Hernandez, Nghia H. Nguyen, Rohan Khera, Rohit Loomba, Sumeet K. Asrani, Siddharth Singh
Summary: Around one-third of adults with CLD experience financial hardship from medical bills and often encounter financial toxicity and unplanned healthcare use.
Review
Gastroenterology & Hepatology
Nghia H. Nguyen, Ivonne Martinez, Ashish Atreja, Amy M. Sitapati, William J. Sandborn, Lucila Ohno-Machado, Siddharth Singh
Summary: Digital health interventions have the potential to reduce healthcare utilization and costs in the management of patients with inflammatory bowel diseases. However, there is limited evidence to support their impact on disease activity, treatment adherence, and quality of life.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Gastroenterology & Hepatology
Nghia H. Nguyen, Jiyu Luo, Paulina Paul, Jihoon Kim, Gaurav Syal, Christina Ha, Vivek Rudrapatna, Sunhee Park, Nimisha Parekh, Kai Zheng, Jenny S. Sauk, Berkeley Limketkai, Phillip Fleshner, Samuel Eisenstein, Sonia Ramamoorthy, Gil Melmed, Parambir S. Dulai, Brigid S. Boland, Uma Mahadevan, William J. Sandborn, Lucila Ohno-Machado, Dermot McGovern, Siddharth Singh
Summary: Hispanic patients with IBD who are treated with biologic therapy have a higher risk of hospitalization, surgery, and serious infections compared to non-Hispanic patients. Further research is needed to investigate the biological, social, and environmental factors underlying these differences.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
